1. Introduction
===============

Risk stratification is crucial to the appropriate management of patients with Acute Coronary Syndrome (ACS) \[[@r1]\]. Current validated methods of risk stratification include the Global Registry of Acute Coronary Events (GRACE) and Thrombolysis In Myocardial Infarction (TIMI) risk scores, both of which use the presence of elevated biomarkers as an adverse risk factor \[[@r2]\]. Studies have demonstrated that incorporating novel non-necrosis biomarkers into standard risk scores can improve risk prediction \[[@r3], [@r4]\]. Heart Type Fatty Acid Binding Protein (HFABP) is a small cytosolic protein primarily responsible for the transport of long chain fatty acids, which is released rapidly into the serum during myocardial infarction \[[@r5], [@r6]\]. A number of analyses have demonstrated improved risk stratification of suspected ACS patients when HFABP is used as a biomarker \[[@r7]\].

2. Objectives
=============

The purpose of this systematic review was to determine the absolute prognostic value of HFABP levels in patients with suspected or confirmed ACS, the incremental prognostic value beyond standard risk stratification and troponin levels, and the clinical utility of measuring HFABP in these patients.

3. Methods
==========

A systematic review was conducted with adherence to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) 2009.

4. Study eligibility
====================

We included studies investigating the prognostic role of HFABP in patients with suspected or confirmed ACS. Pre-specified inclusion criteria were prospective studies (including post hoc analysis from prospective studies) with human adult patients who had HFABP measured during the index admission with at least 1 month follow up data.

5. Study definitions
====================

A prognostic event was defined as all-cause mortality or Acute Myocardial Infarction (AMI).

6. Search strategy
==================

The primary search was performed using NHS Evidence to identify suitable English language articles from inception to July 2015 from Medline, Pubmed and Embase databases. The search included HFABP in association with ACS, angina and coronary disease as key terms. Only human studies were allowed. Review articles were not included. Studies were excluded in the absence of complete or potentially extractable data considered necessary to determine the prognostic value of HFABP in patients with suspected or confirmed ACS. Results in abstract-only and poster format were not included. All studies identified had their references hand-searched and scrutinised in order to identify other potential studies for inclusion.

7. Data extraction
==================

The primary literature search was performed by an in-house clinical information specialist trained in literature searches and a clinician (JJ). The literature search, scrutiny of abstracts and relevant full texts of all identified studies was undertaken by two authors (JJ and RD) independently and without cross-reference. Disagreements in inclusion or exclusion of articles between the two authors were adjudicated by a 3^rd^ researcher (AK) by reference to the inclusion criteria detailed above.

8. Quality of Studies
=====================

Each study was assessed for its quality by two reviewers (JJ, AK) using the American Heart Association guidance for the evaluation of novel markers of cardiovascular risk (Table **[1](#T1){ref-type="table"}**), \[[@r8]\] and, by other quality markers determined by the authors (Table **[1](#T1){ref-type="table"}**).

The quality of studies was evaluated as to the presence of a clearly defined aim (of determining the prognostic value of HFABP in ACS), if the population studied was similar to a \'real life\' suspected ACS population and the appropriateness of sample timing.

9. Results
==========

9.1. Study Selection
--------------------

The primary search and cross referencing identified 276 manuscripts (Fig. **[1](#F1){ref-type="fig"}**). From the articles identified, 269 were excluded from the review. The majority of papers were excluded as the article was not addressing an ACS population or no prognostic information was provided. See Fig. (**[1](#F1){ref-type="fig"}**) for full list of exclusion criteria. 118 full text articles were reviewed in order to obtain the final 7 trials providing data on 6,935 patients for this systematic review (Fig. **[1](#F1){ref-type="fig"}**).

9.2. Quality of Studies
-----------------------

The majority of studies had clearly defined aims. Reiter *et al*. \[[@r9]\], Ishii *et al*. \[[@r10]\] and McCann *et al*. \[[@r11]\] were prospective observational studies with pre-specified aims. Viswanathan *et al*. \[[@r12]\] had the clear aim of establishing the prognostic value of HFABP in patients with suspected ACS, with intended focus on the low to intermediate risk patients. However patients were recruited, regardless of initial risk/troponin levels. O\'Donoghue *et al*. \[[@r13]\] Kilcullen *et al*. \[[@r7]\] and Ilva *et al*. \[[@r14]\] were post-hoc analyses.

9.3. Timing of Sample Acquisition
---------------------------------

At the onset of myocardial infarction HFABP rises rapidly and reaches peak levels within 4 to 8 hours, then falls rapidly and return to baseline within 24 hours \[[@r15]-[@r17]\]. Each study obtained samples for HFABP at different times (Table **[2](#T2){ref-type="table"}**). Reiter *et al*. \[[@r9]\] and Ishii *et al*. \[[@r10]\] did not report the timing of sampling. Kilcullen *et al*. \[[@r7]\] measured HFABP between 12-24 hours after symptom onset; samples taken nearer to 24 hours may lead to an underestimation of the risk associated, as levels may have returned to normal by the time sampling had occurred. O\'Donoghue *et al*. \[[@r13]\] were those who reported the timings of samples on patients who clearly fall outside of this initial rise of HFABP in ACS; any correlation with HFABP and prognosis in this study is more likely to represent a different pathophysiology, such as on-going ischaemia.

9.4. Trial Population and Demographics
--------------------------------------

Study and participant characteristics were extracted (Table **[2](#T2){ref-type="table"}, [3](#T3){ref-type="table"}**). The trial population was mostly male, in common with most clinical trials. There was considerable variability in the subtype of ACS between studies, reflected in the differences in inclusion criteria. All studies included patients with myocardial infarction and Viswanathan *et al*. \[[@r12]\] alone excluded those with STEMI. Reiter *et al*. \[[@r9]\] and McCann *et al*. \[[@r11]\] were those who specifically described HFABP and outcome in those with a final diagnosis of non-cardiac chest pain. Other clinical characteristics appeared similar between studies. Each study had differing durations of follow up and end points (Table **[3](#T3){ref-type="table"}**).

9.5. Biomarker Assays
---------------------

There are currently no international analytical standards for HFABP analysis. However, each study except for those by McCann *et al*. \[[@r11]\] and Ilva *et al*. \[[@r14]\] provided information regarding the precision of the HFABP analysis (Table **[3](#T3){ref-type="table"}**). Troponin assays varied between studies. There has been considerable change in troponin assays over recent years, particularly with the development of higher sensitive troponin assays. High sensitive troponin are generally understood to be those with a coefficient of variation of 10% or less at the 99^th^ percentile with the ability to detect cardiac troponin in at least 50% of the reference population \[[@r18], [@r19]\]. Only the study by Reiter *et al.* used troponin assays (Hs Tn T \[Roche\]) that fulfilled this definition.

9.6. Prognostic Impact of Elevated HFABP
----------------------------------------

All included studies demonstrated that HFABP provides (unadjusted) prognostic information (Table **[4](#T4){ref-type="table"}**). The studies analysing the end points mortality and combined mortality/AMI found higher levels of HFABP were associated with a worse prognosis. All three studies by Mccann \[[@r11]\], O'donoghue \[[@r13]\] and Ishi \[[@r10]\] analysing the end point of acute MI in isolation, found that there was no statistically significant association with HFABP levels, although there was a trend towards significance in the study by O'Donoghue *et al*. \[[@r13]\] (RR 1.7, p=0.053). All studies demonstrated a strong linear relationship between HFABP level, when categorised, in subgroups rather than as a dichotomous variable, and the hazard ratio of hard endpoints (Table **[5](#T5){ref-type="table"}**).

Analyses were undertaken in all studies to determine the incremental value of abnormal HFABP by adjusting for a range of covariates (Table **[6](#T6){ref-type="table"}**). No authors looked directly at the incremental value of HFABP beyond calculated traditional risk scores such as the GRACE or TIMI score. Kilcullen *et al*. \[[@r7]\] used GRACE variables plus high sensitivity C reactive protein (hs-CRP) with troponin I as a continuous variable but did not define incremental values against a summative GRACE score. Viswanathan *et al*. \[[@r12]\], Kilcullen *et al*. \[[@r7]\] and O\'Donoghue *et al*. \[[@r13]\] demonstrated that HFABP retains prognostic power even when troponins are incorporated in the multivariable regression model.

Troponin and HFABP provided complimentary risk information in the studies by Kilcullen *et al.* \[[@r7]\] and Reiter *et al*. \[[@r9]\]. Both Kilcullen *et al*. \[[@r7]\] and Reiter *et al*. \[[@r9]\] demonstrated the incremental value of HFABP beyond troponin. Both studies \[[@r7], [@r9]\] revealed zero to 6-month mortality if both HFABP and troponin levels were within normal limits. In patients with raised troponin levels, Kilcullen *et al*. \[[@r7]\] demonstrated elevated HFABP was associated with a 25% mortality over 12 months, compared with \<5% mortality for those with HFABP levels within normal range. In comparison, Reiter *et al*. \[[@r9]\] discovered a mortality of 20% and 3% over 2 years in those with elevated HFABP versus HFABP in the normal range respectively. In patients with normal troponin levels, Kilcullen *et al*. \[[@r7]\] demonstrated that an elevated HFABP was associated with a 20% mortality at 1 year (compared to \<3% annual mortality with normal HFABP levels). This contrasts with the study by Reiter *et al*. \[[@r9]\] who discovered that HFABP did not differentiate risk in patients with normal troponin levels at 2 years.

Three studies analysed outcome by absolute HFABP values rather than as a dichotomous variable. They revealed increasing risk with increasing HFABP values. They revealed unadjusted and adjusted prognostic outcome of subgroups of ACS according to HFABP levels (Table **[6](#T6){ref-type="table"}**). Prognostic information is present across the entire spectrum of ACS.

9.7. Coronary Revascularisation
-------------------------------

Coronary revascularisation rates could confound prognostic assessment of biomarkers including HFABP. Reiter *et al*. and Ilva *et al*. \[[@r9], [@r14]\] did not describe revascularisation rates (Table **[4](#T4){ref-type="table"}**). Of the others only O'Donoghue *et al*. \[[@r13]\] and Kilcullen *et al*. \[[@r7]\] described revascularisation rates according to HFABP level. There was no apparent difference in coronary revascularisation rates between HFABP subgroups in these 2 studies. However, there was a numerically lower revascularisation rates in the highest quartile of HFABP compared to the lowest quartile in the study by Kilcullen *et al*. \[[@r7]\].

9.8. Assessment of Heterogeneity and Publication Bias Inclusion Criteria ([Fig. 2](#F2){ref-type="fig"})
--------------------------------------------------------------------------------------------------------

Study end points and length of follow up and method of reporting varied considerably between studies, making pooling of data or direct comparison difficult. For the purpose of visually assessing the effect sizes between studies we constructed a funnel plot. The odd ratios for the mortality associated with elevated HFABP are illustrated in Fig. (**[2](#F2){ref-type="fig"}**) from 6 of the 7 studies where individual mortality data was able to be discriminated \[[@r7], [@r9], [@r10], [@r12]-[@r14]\]. The point estimate with 95% confidence intervals in Fig. (**[2](#F2){ref-type="fig"}**) was derived from a weighted combination of risk derived from normal versus elevated HFABP populations in these 6 studies. (Reviewmanager 5.3, Cochrane informatics and knowledge management department). There is an evidence of marked heterogeneity in odds ratio with these studies. The very large confidence limits with data by Ishii *et al*. \[[@r10]\] and McCann *et al*. \[[@r11]\] reflect mainly a small number of events and imply uncertainty over the true hazard risk associated with an abnormal HFABP. The odd ratios of death conferred by an abnormal HFABP in the study by Kilcullen *et al*. \[[@r7]\] and O'Donoghue *et al*. \[[@r13]\] appear more robust with narrower confidence intervals. This difference in odds ratio and the marked differences in point estimates outside the 95% confidence interval in these studies is more likely a reflection of methodological differences and population risk rather than publication bias.

10. Discussion
==============

We have systematically reviewed the role of HFABP as a prognostic biomarker in patients with suspected ACS. As far as we are aware, no previous such analysis has been undertaken to gain further insight into the potential clinical utility of HFABP as a prognostic biomarker for suspected ACS. We report 3 major findings from this systematic review: The evidence for the use of HFABP as a biochemical marker for risk stratification in acute coronary syndromes is weak with heterogeneous studies and lack of consistency in both timing of measurement post-acute coronary syndrome and precision of assay used. Its incremental value beyond 5^th^ generation high sensitive troponins has been evaluated in only one study. Currently there is insufficient evidence to consider its use as a prognostic marker in acute coronary syndrome.

Heart-type fatty acid-binding protein (hFABP) is a small soluble cytosolic protein involved in the transportation of long-chain fatty acids into the cardiomyocyte. It may enter the vascular system directly *via* endothelium because of its small size. It is released rapidly into the circulation in response to cardiomyocyte injury. Due to its solubility, HFABP can be released more rapidly than structurally bound molecules like cardiac troponins and therefore it is an early marker of myocardial ischaemia (for rule-out myocardial infarction in combination with troponins) \[[@r20]\]. However, it is not certain whether release into the circulation in the event of myocardial ischaemia/ necrosis is earlier than high sensitive troponins. HFABP raised in acute myocardial ischaemia even in the absence of myocyte necrosis (troponin negative- 4^th^ generation troponin) and therefore it is proposed as a powerful prognostic tool in acute coronary syndrome (and in particular unstable angina) \[[@r7], [@r12]\].

All of the studies evaluated in this systematic review, indicate that HFABP does provide some prognostic information in patients with suspected ACS to varying degrees. Only one of the seven studies concluded that the significance of this prognostic information was not present after adjusting for covariates.

However, before contemplating the merits of HFABP, it is important to consider the parameters necessary to consider a biomarker as a clinically useful and cost-effective tool in clinical practise. Statistical methods including odds ratios, risk ratios and hazard ratios may not be the most appropriate technique for determining the clinical utility of a biomarker. The desirable features for a prognostic biomarker of atherosclerotic cardiovascular disease have already been proposed \[[@r21]\]. Although HFABP appears to add to the clinical assessment of patients, it is not known whether HFABP can alter management or lead to an improvement in health outcome

Perhaps the most clinically interesting aspects identified in this review was the incremental value of HFABP beyond troponin as demonstrated by Kilcullen *et al*. \[[@r7]\] and Reiter *et al*. \[[@r9]\]. HFABP elevation in the presence of a normal troponin may reflect myocardial ischaemia and could lead to greater potential myocardial salvage if an early interventional strategy is adopted. Patients with normal troponin and HFABP levels appear to predict a very low risk population group, which may benefit from early hospital discharge. However, both of these hypotheses are untested.

Studies investigating whether HFABP leads to risk reclassification beyond internationally recognised validated risk scores and contemporary high sensitivity troponin assays, would be welcomed by the authors. Moreover, randomised studies comparing the measured health outcome for patients who have HFABP determined and receive an intervention tailored to HFABP levels, with those who do not have HFABP measured and receive standard intervention would be required before the assay can be considered for routine clinical practice.

10.1. Limitations
-----------------

We conducted an extensive comprehensive review, nevertheless a number of limitations persist. The primary search was performed using extremely large and reliable databases, which leads to the potential introduction of database bias. Differences in the designs of the trials, with differing sampling intervals and cut-of points, precluded a meta-analysis or an easy summation of evidence thus reducing the overall power of this analysis.

10.2. Publication Bias
----------------------

Fig. (**[2](#F2){ref-type="fig"}**) and Table **[4](#T4){ref-type="table"}** suggest marked heterogeneity in odds ratio relative risk with elevated HFABP for our outcome measures. This could indicate publication bias with a preponderance of 'positive studies' for HFABP. However it could also be explained by a difference in methodology, timing of samples and troponin assays used.

Conclusion
==========

Each of the studies identified in this review concluded that HFABP provides some prognostic information in patients with suspected or confirmed ACS. Only one of the seven studies concluded that the significance of this prognostic information was not present after adjusting for covariates. The data suggest that regardless of the subtype of ACS, patients with \'high\' HFABP levels are at higher risk of death or myocardial infarction at any time during the follow-up compared with those with \'low\' HFABP levels. However, there is insufficient evidence to currently recommend its uptake, as a clinical tool, in decision-making patients with suspected ACS. Additional studies, particularly randomised control studies are required to investigate the outcome for early discharge of patients who are high sensitive troponin negative and HFABP negative against standard care (high sensitive troponin alone with clinical judgement and ECG). Also it would be prudent to investigate intermediate risk patients with randomisation to an invasive strategy in event of HFABP positivity against routine care. Such studies would add greatly to the evidence base and also allow a determination of cost-effectiveness of a HFABP 'enabled' strategy.
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###### 

Study quality based on criteria for evaluation of a novel biomarker.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Novel marker reported:**                                                                                   **Reiter \[** [@r9] **\]**   **Viswanathan \[** [@r12] **\]**   **McCann \[** [@r11] **\]**   **Ilva \[** [@r14] **\]**   **Kilcullen \[** [@r7] **\]**   **O'Donoghue \[** [@r13] **\]**   **Ishii \[** [@r10] **\]**
  ------------------------------------------------------------------------------------------------------------ ---------------------------- ---------------------------------- ----------------------------- --------------------------- ------------------------------- --------------------------------- ----------------------------
  In accordance with STROBE \[[@r19]\]                                                                         ++                           ++                                 ++                            \+                          ++                              ++                                ++

  a\) Standard RF, and\                                                                                        +++\                         +++\                               +++\                          +++\                        +++\                            +++\                              +++\
  b) results of risk model using established factors                                                           -                            +++                                ++                            ++                          +++                             +++                               +++

  a\) RR, OR, HR with CI/p value\                                                                              \-\                          +++\                               +++\                          \-\                         +++\                            +++\                              +++\
  b) RR, OR, HR adjusted for RF and CI/p value\                                                                +++\                         +++\                               +++\                          -\                          +++\                            +++\                              +++\
  c) p value for addition of novel marker to standard risk markers.                                            -                            +++                                +++                           -                           +++                             -                                 +++

  a\) C-index and CL for model with established risk markers\                                                  \+\                          \+\                                \-\                           \-\                         \-\                             \-\                               \+\
  b) C-index and CL for model including novel and established risk markers\                                    +\                           +\                                 -\                            -\                          -\                              -\                                +\
  c) Discrimination index/slope or binary R2 for model with and without novel marker.\                         -\                           -\                                 -\                            -\                          -\                              -\                                -\
  d) Graphic display of predicted cases before and after inclusion of the marker.                              -                            -                                  -                             -                           -                               -                                 -

  a\) Display observed *vs.* expected event rates without/ with the novel risk marker.\                        \-\                          \-\                                \-\                           \-\                         \-\                             \-\                               \-\
  b)using generally recognised risk thresholds, subjects reclassified and event rates in reclassified groups   -                            -                                  -                             -                           -                               -                                 -

  Clearly defined aim                                                                                          Good                         Fair                               Good                          Good                        Good                            Good                              Good

  'real-life' population                                                                                       Good                         Good                               Good                          Good                        Fair                            Fair                              Good

  Appropriate sampling period for HFABP release                                                                \-                           Yes                                Yes                           Yes                         Yes                             No                                \-
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

+++ Complete adherence, ++reasonable adherence, +partial adherence, - does not report

RF risk factors, CI Confidence interval, CL confidence limits.

###### 

Patient characteristics.

  **Author**               **Age (years) \[mean± SD/ mean range-range\] unless stated**   **Male (%)**   **Index Diagnosis (%)**   **Past Medical History (%)**                                                                  
  ------------------------ -------------------------------------------------------------- -------------- ------------------------- ------------------------------ ------ ------ ------ ------ ------ ------ ------ ------ ------ -----
  Reiter \[[@r9]\]         Med 64 (IQR 51-76)                                             67             20                        16                             4      11     14\*   25     19     34     64     45     NR     10
  Viswanathan \[[@r12]\]   60.01±15                                                       60.5           20.8                      20.8                           0      79.2   0      30.5   15.1   24.4   61.2   NR     5.1    NR
  McCann \[[@r11]\]        62±13                                                          70.2           52.9                      33.6                           19.2   26     21.1   36.9   17.3   68.2   54.6   76.6   NR     3.6
  Ilva \[[@r14]\]          67.1                                                           61.8           42.0                      22.9                           19.1   NR     4.1    30.7   17.4   18.8   43.7   58.4   10.2   NR
  Kilcullen \[[@r7]\]      Med 72.5± 13                                                   61             87.7                      62.9                           24.8   12.3   0      27.1   16.9   26.1   NR     NR     7.6    NR
  O'Donoghue \[[@r13]\]    38.74% ≥ 65 years                                              71.9           54.9                      22.5                           32.4   45.1   0      NR     21.6   35.9   41.9   28.3   5.2    NR
  Ishii \[[@r10]\]         64.9 ±10.4                                                     80.5           73.5                      NR                             47     NR     0      17.7   32.0   54.3   54.9   44.2   0.9    NR

Abbreviations: NR = not reported, AMI= acute myocardial infarction, NSTEMI- non st segment elevation myocardial infarction, STEMI= st segment elevation myocardial infarction,

UA= unstable angina, DM= diabetes mellitus, HTN= hypertension, HChol= hypercholesteraema, CHF= chronic heart failure, CRF = chronic renal failure, Med= median, \*refers to cardiac non-coronary disease.

###### 

Study design and endpoints.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Author \[reference\]**   **Study design**                  **N**   **Patients included**           **Troponin assay**                                   **HFABP assay**                                      **Time of HFABP sample**                 **Follow up**      **Study end points relevant to review**
  -------------------------- --------------------------------- ------- ------------------------------- ---------------------------------------------------- ---------------------------------------------------- ---------------------------------------- ------------------ --------------------------------------------
  Reiter \[[@r9]\]           Prospective observational study   1074    Suspected ACS                   Roche. HS cTnT.                                      QuickSenshFABP assay                                 NR                                       12 months          All-cause mortality

  Viswanathan \[[@r12]\]     Prospective observational study   955     Suspected ACS                   Siemens Healthcare Diagnostics.\                     Randox Laboratories                                  \< 12 hours post symptom onset           12 months min;\    Composite of death and readmission with MI
                                                                                                       Advia TnI /Advia TnI Ultra.                                                                                                                        median 18 months   

  McCann \[[@r11]\]          Prospective observational study   550     Suspected ACS                   Roche, Elecsys, Troponin T mmunoassay                Human H-FABP ELISA test kit, Hycult, biotechnology   Median time 6 hours post symptom onset   12 months          Composite of death and MI

  Ilva \[[@r14]\]            Post hoc\                         293     Suspected ACS                   Abbott Diagnostic Division.\                         Innotrac Diagnostics (experimental assaty)           0-24 hours post symptom onset            6 months           Death and readmission with MI
                             analysis                                                                  Architect STAT Troponin I assay.                                                                                                                                      

  Kilcullen \[[@r7]\]        Post hoc analysis                 1448    Confirmed ACS EMMANCE-2 study   Beckman Coulter.\                                    Dainippon Pharmaceutical                             12-24 hours post symptom onset           12 months          Death
                                                                                                       Accu TnI assay.                                                                                                                                                       

  O'Donoghue \[[@r13]\]      Post hoc analysis                 2287    Confirmed ACS\                  Biosite Diagnostics. Troponin I assay.               Dainippon Pharmaceutical                             41±20 hours post randomisation.          10 months          Death, MI
                                                                       OPUS-TIMI 16.                                                                                                                                                                                         

  Ishii \[[@r10]\]           Prospective observational study   328     Confirmed ACS                   Roche Diagnostics. Elecsys Troponin T immunoassay.   Dainippon Pharmaceutical                             NR                                       6months            Cardiac death and MI
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

NR = not reported. Revasc = coronary revascularisation, CP= chest pain, CHF= chronic heart failure, MI= myocardial infarction.

###### 

Main study outcomes for entire study cohort.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Study \[ref\], year**       **N**           **Duration of follow up**    **Coronary Revascularisation rates**                      **End point**   **No of events**                        **HFABP cut off for analysis**       **Events in 'lower' HFABP/total in group**   **Events in 'higher' HFABP/total in group**   **Unadjusted risk for 'higher' HFABP levels**   **Adjusted risk for 'higher' HFABP levels**   **Covariates used**
  ----------------------------- --------------- ---------------------------- --------------------------------------------------------- --------------- --------------------------------------- ------------------------------------ -------------------------------------------- --------------------------------------------- ----------------------------------------------- --------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------
  Reiter \[[@r9]\] 2013         1074            12 months                    Not specified                                             Death           \-                                      5.76µg/L.                            \-                                           \-                                            \-                                              aHR 1.017 (1.007 -- 1.029) p = 0.002          Age, gender, cardiovascular risk factors

  Viswanathan \[[@r12]\] 2010   955             \>12 months                  8.1%(inpatient revascularisation noted only)              Death or MI     96                                      6.48µg/l                             48/838                                       48/117                                        uRR 7.16 (5.05-10.17) p\<0.0001\                aHR 2.62 (1.3-5.28) p = 0.007                 Age, DM, HTN, previous HF, previous MI, admission HR, ST Depression, Creatinine, Tn
                                                                                                                                                                                                                                                                                                                               uOR 11.45 (7.16-18.31) p \<0.0001                                                             

  McCann \[[@r11]\] 2009        550             12 months                    PCI 38%\                                                  Death           29                                      5µg/l                                \-                                           \-                                            uOR 21.2 (2.9 -- 157.3) p = 0.003               aOR 10.5 (1.4-80.6)\                          Age, gender, risk factors, cardiac history, SBP, Killip class, ECG, eGFR, WCC, Tn, investigational biomarkers.
                                                                             CABG 8%                                                                                                                                                                                                                                                                                           p=0.023                                       

  Death or MI                   54              uOR 5.4(2.4-12.2) p\<0.001   aOR 2.7 (1.1-6.4) p = 0.028                                                                                                                                                                                                                                                                                                                     

  MI                            31              Not significant              Not significant                                                                                                                                                                                                                                                                                                                                 

  Ilva \[[@r14]\] 2008          293             6 months                     Not specified                                             Death or MI     43                                      10.4µg/l                             18/183                                       25/110                                        uRR\* 2.31 (1.32-4.04) p = 0.0033\              Not significant                               Age, gender, DM, Chol, HTN, Smoker, prev MI, Prev revasc, Killip Class, ST deviation, Tn.
                                                                                                                                                                                                                                                                                                                               uOR\* 2.7 (1.39 -- 5.22 p = 0.0032                                                            

  Kilcullen \[[@r7]\] 2007      1448            12 months                    PCI 7.4%\                                                 Death           296                                     5.8µg/l                              11/305                                       285/1143                                      uRR\* 6.91 (3.84 -- 12.46) p \< 0.0001\         \-                                            
                                                                             CABG 2.6% (both inpatient revascularisation noted only)                                                                                                                                                                                           uOR\* 8.88 (4.79 -- 16.45) p \<0.0001                                                         

  O'Donoghue \[[@r13]\] 2006    2287            30 days                      PCI for index event 33.9%                                 MI              \-                                      8µg/l                                \-                                           \-                                            uHR 1.9 (1.04-3.4)\                             \-                                            Demographics, clinical characteristics, time to randomisation, index diagnosis, creatinine clearance, ST deviation, Biosite Tn
                                                                                                                                                                                                                                                                                                                               p=NR                                                                                          

  10 months                     Death           102                          61/1955                                                   41/332          uHR 4.1 (2.6-6.5) p\<0.001              aHR 2.7 (1.5-4.9)\                                                                                                                                                                                                            
                                                                                                                                                                                               p=NR                                                                                                                                                                                                                          

  10 months                     MI              140                          109/1955                                                  31/332          uHR 1.6 (1-2.5) p=0.053                 \-                                                                                                                                                                                                                            

  Ishii \[[@r10]\], 2005        328             30 days                      PCI 55.5%\                                                Cardiac death   14                                      9.8µg/l                              1/164                                        13/164                                        uRR\* 13 (1.72 -- 98.24) p = 0.0129\            \-                                            Age, gender, time from chest pain, STEMI, Tn, Creatinine, Killip class, Anterior AMI, previous MI.
                                                                             CABG 5.2%                                                                                                                                                                                                                                         uOR\* 14.03 (1.81 -- 108.57) p = 0.0114                                                       

  30 days                       Death or MI     18                           3/164                                                     15/164          uRR\* 4.7 (1.38 -- 16.03) p = 0.0136\   \-                                                                                                                                                                                                                            
                                                                                                                                                       uOR\* 5.42 (1.53 -- 19.03) p = 0.0087                                                                                                                                                                                                                                 

  6 months                      Cardiac death   15                           1/164                                                     14/164          uRR 14.5 (1.91 -- 110.5) p = 0.009      aRR 8.92 (1.15 -- 69.4) p = 0.04                                                                                                                                                                                              

  6 months                      Death or MI     25                           3/164                                                     22/164          uRR 7.7 (2.3 -- 25.7)\                  aRR 8.96 (2.64 -- 30.4) p = 0.0004                                                                                                                                                                                            
                                                                                                                                                       p = 0.0009                                                                                                                                                                                                                                                            

  6 months                                      MI                           10                                                        2/164           8/164                                   uRR\* 4 (0.86-18.55)\                                                                                                                                                                                                         
                                                                                                                                                                                               p=0.076                                                                                                                                                                                                                       
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Calculated by author using raw data. - = Not reported.

###### 

Outcome according to absolute value ranges of HFABP.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Study \[ref\], year**        **Covariates included**                                                            **Risk of higher HFABP in patients with ACS**
  ------------------------------ ---------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------
  Viswanathan \[[@r12]\], 2010   Unadjusted                                                                         Death or MI HR (95% CI) according to HFABP level\
                                                                                                                    HFABP 0.15-3.26 µg/l HR 1, p = \<0.001.\
                                                                                                                    HFABP 3.27-6.48 µg/l HR 3.41 (1.89 -- 6.16) p = 0.001\
                                                                                                                    HFABP 6.49-12.77 µg/l HR 15.67 (8.16-30.07) p = \<0.001.\
                                                                                                                    HFABP 12.78-151.0 µg/l HR 20.37 (10.38-40.00) p =\<0.001.

  Kilcullen, \[[@r7]\] 2007      Unadjusted                                                                         All-cause mortality HR (95% CI) according to HFABP level\
                                                                                                                    HFABP \< 6.38µg/l HR 1.\
                                                                                                                    HFABP 6.38-12.39µg/l HR 4.45 (2.47-8) p \<0.001.\
                                                                                                                    HFABP 12.39 -- 36.2µg/l HR 8.78 (4.99-15.46) p \< 0.001.\
                                                                                                                    HFABP \> 36.2µg/l HR 11.69 (6.67-20.49) p \<0.001.

  O Donoghue \[[@r13]\], 2006    Unadjusted                                                                         Death rate 10 months (p\<0.001)\
                                                                                                                    HFABP \<8 µg/l 3.1%\
                                                                                                                    HFABP 8-16 µg/l 6.9%\
                                                                                                                    HFABP \>16 µg/l 18%\
                                                                                                                    MI rates 10 months (p=0.009)\
                                                                                                                    HFABP \<8 µg/l 5.6%\
                                                                                                                    HFABP 8-16 µg/l 5.5%\
                                                                                                                    HFABP \>16 µg/l 13.8%

  Viswanathan, \[[@r12]\] 2010   Age, DM, HTN, previous HF, Previous MI, HR, ST depression, creatinine, troponin.   Death or MI median 18 month\
                                                                                                                    HFABP 0.15 -- 3.26 µg/l HR 1, p = 0.003.\
                                                                                                                    HFABP 3.27 -- 6.48 µg/l HR 0.78 (0.39 -- 1.55) p = 0.48.\
                                                                                                                    HFABP 6.49 -- 12.77 µg/l HR 2.62 (1.30 -- 5.28) p = 0.007.\
                                                                                                                    HFABP 12.78 -- 151.0 µg/l HR 1.54 (0.55 -- 4.32) p = 0.41.

  Kilcullen, \[[@r7]\] 2007      GRACE risk factors, and inpatient PCI and HS CRP.                                  HFABP quartiles adjusted for GRACE risk factors plus hs-CRP with TnI as continuous variable.\
                                                                                                                    HFABP \< 6.38µg/l HR 1.\
                                                                                                                    HFABP 6.38-12.39µg/l HR 2.32 (1.25 -- 4.30) p = 0.007.\
                                                                                                                    HFABP 12.39 -- 36.2µg/l HR 3.17 (1.73 -- 5.82) p \< 0.001.\
                                                                                                                    HFABP \> 36.2µg/l HR 4.88 (2.67 -- 8.93) p \<0.001.
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Unadjusted and covariate adjusted risk of elevated HFABP.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Unadjusted risk**                                                                                                                                                             
  ----------------------------- ------------------- ----------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------
  Normal troponin levels        Viswanathan, 2010   Death or MI HR (95% CI) according to HFABP level\                                                                             
                                                    HFABP 0.15-3.26 µg/l HR 1\                                                                                                    
                                                    HFABP 3.27-6.48 µg/l HR 3.46 (1.69 -- 7.10) p = 0.001\                                                                        
                                                    HFABP 6.49-12.77 µg/l HR 11.20 (4.95-25.36) p \<0.001.\                                                                       
                                                    HFABP 12.78-151.0 µg/l HR 16.64 (2.21-125.51) p = 0.006.\                                                                     
                                                    HFABP \>5.3 ♀ and \>5.8 ♂\                                                                                                    
                                                    HR 6.57 (3.05 -- 14.11) p 0.0001\                                                                                             
                                                    Subgroup analysis of 384 patients with additional admission sample taken for HFABP\                                           
                                                    HR 5.08 (1.84 -- 14.07) p = 0.002                                                                                             

  Normal troponin levels        Kilcullen, 2007     HFABP \< 6.38µg/l HR 1.\                                                                                                      
                                                    HFABP 6.38-12.39µg/l HR 6.50 (1.53 -- 27.71) p = 0.011\                                                                       
                                                    HFABP 12.39 -- 36.2µg/l HR 5.79 (1.08 -- 31.12) p = 0.041\                                                                    
                                                    HFABP \> 36.2µg/l HR unable to calculate, as no deaths.                                                                       

  **Covariate adjusted risk**                                                                                                                                                     

  **Subgroup**                  **Study**           **Covariates included**                                                                                                       **Risk**

  Normal troponin levels        Viswanathan, 2010   Age, DM, HTN, HF, previous MI, HR, ST depression, Creatinine, troponin.                                                       HFABP \>5.8µg/l adjusted HR (for GRACE Risk Factors and Hs CRP and tnI as continuous variable)\
                                                                                                                                                                                  aHR 11.35 (2 -- 64.34, p = 0.006).\
                                                                                                                                                                                  Death and MI Adjust HR (age and creatinine):\
                                                                                                                                                                                  HFABP 0.15 -- 3.26 µg/l HR 1, p = 0.01.\
                                                                                                                                                                                  HFABP 3.27 -- 6.48 µg/l HR 1.55 (0.72 -- 3.36) p = 0.26\
                                                                                                                                                                                  HFABP 6.49 -- 12.77 µg/l HR 3.12 (1.11 -- 8.76) p = 0.03.\
                                                                                                                                                                                  HFABP 12.78 -- 151.0 µg/l HR 16.67 (2.19 -- 127.06) p = 0.007.

  Normal troponin levels        Kilcullen, 2007     GRACE risk factors, HS CRP and TnI as additional continuous variable                                                          All-cause mortality HR if HFABP \> 5.8 µg/L\
                                                                                                                                                                                  HR 11.35 (2 -- 64.34).

  STEMI                         Kilcullen, 2007     GRACE risk factors, HS CRP and TnI as additional continuous variable                                                          no deaths in the group with HFABP levels ≤5.8 µg/l.\
                                                                                                                                                                                  77 deaths in STEMI subgroup, all HFABP levels \>5.8 µg/l.\
                                                                                                                                                                                  HR assessment not possible

  STEMI                         Ishii               Age, gender, time from onset chest pain, increased cTnT, creatinine, Kilip class \>1, anterior AMI, previous history of MI.   Cardiac death or MI if HFABP \>9.8 µg/L\
                                                                                                                                                                                  RR 11.3, 1.41 -- 90.6, p=0.02

  NSTEMI                        Kilcullen, 2007     GRACE risk factors, HS CRP and TnI as additional continuous variable                                                          All cause mortality\
                                                                                                                                                                                  aHR 3.11 (1.45 -- 6.7) p = 0.004.

  NSTEMI                        Ishii, 2005                                                                                                                                       For both UA and NSTEMI patients HFABP \>9.8µg/L --\
                                                                                                                                                                                  aRR 8.31 (1.76 -- 39.1) p = 0.007
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

MI = Myocardial infarction.
